+86-28-82633987
Product Name: Senegenin
Synonym name: Tenuigenin; Tenuifolic acid
Catalogue No.: BP1286
Cas No.: 2469-34-3
Formula: C30H45ClO6
Mol Weight: 537.134
Botanical Source: Polygala senega. Derived from Presenegenin by treatment with HCl. Also from Polygala tenuifolia and Bredemeyera floribunda
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Can be supplied from milligrams to grams.
For Reference Standard and R&D, Not for Human Use Directly.
Inquire for bulk scale.
HPLC of Senegenin
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
115.0600
4.6503
1.5356
.0137
2.8448
1.8602
Low
89.9315
5.3329
No
No
No
No
Yes
No
0.3
Yes
No
Yes
No
Senegenin, CAS number 2469-34-3, is a 12α-hydroxysteroid compound with significant neuroprotective activity. As an important active ingredient in the traditional Chinese medicine Polygala tenuifolia Willd., polygala tenuifolia willd. Polygala saponins have gradually attracted widespread attention in research on the prevention and treatment of neurodegenerative diseases. In recent years, with the rapid development of neuroscience and molecular pharmacology, the pharmacological effects and molecular mechanisms of Polygala saponins have been deeply explored, demonstrating their potential therapeutic value in neurological diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD).
This paper will systematically review the chemical structure and physicochemical properties of Polygala saponins, plant origins, and extraction methods, with a focus on their neuroprotective pharmacological activities and mechanisms. Combining druggability parameters and pharmacokinetic characteristics, it explores their clinical application prospects and future research directions, aiming to provide comprehensive and in-depth reference materials for researchers in the field of natural product pharmacology.
Polygala saponin belongs to 12α-hydroxysteroid compounds with a molecular formula of C30H46O6 and a molecular weight of 537.1370. Its structural feature is the introduction of a hydroxyl group at position 12 of the steroid backbone, giving it a unique spatial configuration and bioactivity. The LogP value of Polygala saponins is 4.6503, indicating strong lipid solubility, and the TPSA (Topological Polar Surface Area) is 115.0600, indicating moderate polarity and certain cell membrane penetration capability.
Low water solubility (0.0137 mg/mL) suggests limited solubility in the aqueous phase, which may affect its bioavailability. The blood-brain barrier (BBB) has low permeability, suggesting its limited ability to directly enter the central nervous system, but this does not rule out its neuroprotective role through indirect mechanisms. The hERG channel inhibition test results were negative, indicating that Yuan Zhi saponin carries a low risk of prolonged cardiac QT intervals. The Ames mutagenic test scored 0.3, indicating a low genotoxicity risk and a solid safety foundation.
Polygala saponins are mainly found in the roots and rhizomes of the medicinal herb Polygala. Polygala is a perennial herbaceous plant widely distributed in northern and northeastern China, and is an important herb in traditional Chinese medicine for brain health, intelligence, and calming the mind. Polygala saponins, as the deglycosylated form of Polygala saponins, are usually obtained by hydrolyzing Polygala saponins.
The extraction method mostly uses organic solvent extraction combined with acid-base hydrolysis technology. Common processes include:
In recent years, the application of ultrasound-assisted extraction and microwave-assisted extraction technologies has improved extraction efficiency and purity, reduced extraction time and solvent consumption, and provided technical support for the preparation of Polygala saponins.
Pharmacological research on Yuan Zhi saponin mainly focuses on its neuroprotective effects, showing significant neuroprotective effects in various neurological disease models.
Polygala saponins can reduce nerve cell damage, inhibit neuroinflammation, and protect neuronal survival. In vitro cell models show that Yuanzhi saponins can effectively resist apoptosis induced by oxidative stress and promote neuron survival rates. In vivo experiments, Yuan Zhi saponin improved cognitive impairment and alleviated cerebral ischemia-reperfusion injury, demonstrating its strong neuroprotective potential.
Polygala saponins alleviate the pathological features of AD by regulating β-amyloid (Aβ) metabolism and tau protein abnormalities. It can downregulate BACE1 enzyme activity, reduce Aβ production, promote APP non-amyloid pathway metabolism, and decrease neurotoxic Aβ accumulation. Additionally, polygala saponins inhibit excessive phosphorylation of tau protein and slow down the formation of nerve fiber tangles.
Polygala saponins activate the nuclear factor E2-related factor 2 (NRF2) signaling pathway, enhancing cellular antioxidant defenses and reducing oxidative stress damage. At the same time, it inhibits the release of pro-inflammatory cytokines, reduces neuroinflammatory responses, and protects the stability of the nervous environment.
Polygala saponin also exhibits inhibitory activity against acetylcholinesterase (ACHE), raising acetylcholine levels in the brain and improving cognitive function. Additionally, its regulation of apoptosis-related protein CASP3 promotes nerve cell survival.
The neuroprotective effects of Polygala saponins involve multiple signaling pathways and key molecular targets, with the specific mechanisms as follows:
Polygala saponins upregulate the expression of the anti-apoptotic protein BCL2, inhibit the activity of the pro-apoptotic protein CASP3, reduce neuronal apoptosis, and maintain neuronal survival.
By inhibiting the activity of the β-secretase BACE1, it reduces Aβ produced by APP cleavage, lowers neurotoxic Aβ aggregation, and alleviates pathological progression of AD.
Polygala saponins regulate the phosphorylation status of microtubule-associated protein tau (MAPT), reducing nerve fiber tangling formation and protecting neuronal structural integrity.
SIRT1, as an important deacetylase, is involved in regulating cellular metabolism and anti-inflammatory responses. Polygala saponin activates SIRT1, promoting neuron survival and functional recovery. NRF2 pathway activates and enhances antioxidant enzyme expression, resisting oxidative stress.
Yuan Zhi saponin regulates MAPK1 (ERK2) signaling, influences cell proliferation, differentiation, and stress responses, and promotes nerve cell repair.
Polygala saponins inhibit ACHE, prolonging the duration of acetylcholine in the synaptic cleft and improving cognitive function.
In Parkinson's disease-related research, Yuan Zhi saponin regulates SNCA expression, reduces abnormal aggregation of α-synuclein proteins, and protects dopaminergic neurons.
In summary, Polygala saponins exert comprehensive neuroprotective effects through multi-target and multi-pathway synergistic effects.
The druggability parameters of Polygala saponin indicate that it has certain development potential, but also faces challenges.
The LogP value of Polygala saponin was 4.65, indicating high lipid solubility that facilitates lipid membrane penetration, but low water solubility (0.0137 mg/mL) limits oral absorption. The blood-brain barrier has low permeability, suggesting limited direct access to the central nervous system and may require structural modification or improvement through vector systems.
Currently, there is limited research on the metabolism of polygala saponins in vivo, but it is speculated that they may be metabolized by hepatic enzyme systems, forming various metabolites. Metabolic stability and excretion pathways require further study.
The hERG channel inhibition test was negative, indicating a low risk of cardiac toxicity in Yuan Zhi saponins. The Ames trial scored 0.3, indicating a low genotoxicity risk and a solid safety foundation.
Due to poor water solubility and low BBB permeability, the bioavailability and central nervous system exposure of Polygala saponins are limited. Strategies such as nanocarriers, liposome encapsulation, and structural modification have been proposed to enhance their pharmacokinetic performance.
As a natural steroid compound, Yuanzhi saponin demonstrates broad application prospects in the field of neurodegenerative diseases thanks to its multi-target neuroprotective mechanism.
Yuan Zhi saponin is expected to become a potential therapeutic drug for AD by inhibiting Aβ production, abnormal tau protein, and antioxidant and anti-inflammatory effects. Combined with existing drugs, it can serve as an adjunct therapy to enhance efficacy.
Regulating SNCA expression and antioxidant activity gives it potential application value in PD and other neuroinflammatory diseases.
Through ACHE inhibition and neuroprotection, Yuan Zhi saponin is expected to improve cognitive impairment and is suitable for patients with dementia and brain injury.
As a natural product of 12α-hydroxysteroid with multi-target neuroprotective effects, Yuanzhi saponin demonstrates excellent pharmacological activity and safety. Its potential in the prevention and treatment of neurodegenerative diseases is becoming increasingly prominent, but challenges remain in terms of druggability and pharmacokinetics. In the future, through structural optimization and formulation innovation, it is expected to break through the blood-brain barrier limitations and achieve clinical translation. Systematic pharmacological mechanism research and preclinical evaluation will provide a solid foundation for the development of Yuanzhi saponins, promoting it to become an important model for natural product drug development.
Shenshuai
Wenjing
Hedandan
